Heart Transplantation in post-infarction ventricular septal rupture: Contemporary outcomes from the 2016-2021 National Inpatient Database

Daniel B. Hanna MD , Dhiran Verghese MD , Wael Dakkak MD , Juan Sierra MD , Viviana Navas MD , Luis Paz MD , Travis Howard MD , Mazen Albaghdadi MD , Dee Dee Wang MD , Carl E. Orringer MD , Robert J. Cubeddu MD
{"title":"Heart Transplantation in post-infarction ventricular septal rupture: Contemporary outcomes from the 2016-2021 National Inpatient Database","authors":"Daniel B. Hanna MD ,&nbsp;Dhiran Verghese MD ,&nbsp;Wael Dakkak MD ,&nbsp;Juan Sierra MD ,&nbsp;Viviana Navas MD ,&nbsp;Luis Paz MD ,&nbsp;Travis Howard MD ,&nbsp;Mazen Albaghdadi MD ,&nbsp;Dee Dee Wang MD ,&nbsp;Carl E. Orringer MD ,&nbsp;Robert J. Cubeddu MD","doi":"10.1016/j.jhlto.2025.100278","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Ventricular septal rupture (VSR) is a devastating complication of myocardial infarction (MI), with high mortality, particularly in cardiogenic shock (CS). Heart transplantation (HT) has emerged as a potential alternative to surgery or transcatheter closure (TCC). This study evaluates contemporary trends and outcomes of HT in post-MI VSR using the National Inpatient Sample (NIS) database.</div></div><div><h3>Objectives</h3><div>To assess in-hospital mortality and resource utilization of HT compared to surgical repair or TCC for post-MI VSR with CS.</div></div><div><h3>Methods</h3><div>We analyzed NIS data (2016–2021) for MI-VSR hospitalizations with CS. Patients undergoing HT were compared to those receiving surgical repair or TCC. Primary and secondary endpoints included in-hospital mortality (IHM), total hospital charges (TOTCHG), and length of stay (LOS). Multivariable logistic regression adjusted for age, sex, race, comorbidities, and hospital characteristics, with surgical repair as the control.</div></div><div><h3>Results</h3><div>Of 2,514,025 acute MI hospitalizations, 4765 (0.20%) had VSR. IHM was 82% with CS vs. 60% without. Among VSR-CS patients, 30 (1.2%) underwent HT, 600 (24.1%) surgical repair, 225 (9.2%) TCC, and 1635 (65%) medical therapy. IHM was 0% for HT vs. 66% (surgery), 75% (TCC), and 97% (medical therapy). All HT patients received mechanical circulatory support [IABP (50%), Impella (27%), ECMO ± Impella (10%), ECMO (13%)].). Patients undergoing HT had an average LOS approximately 20 days longer than those treated surgically (p = 0.004; 95% CI: 13.78–47.29) and 15 days longer with TCC (p = 0.008; 95% CI: 19.32–54.23). Similarly, mean total hospital charges (TOTCHG) were higher for HT patients ($1,456,693) compared to surgical repair ($325,032; p = 0.001; 95% CI: $145,002–$634,293) and TCC ($210,032; p = 0.001; 95% CI: $119,230–$542,200).</div></div><div><h3>Conclusions</h3><div>From 2016 to 2021, among VSR-CS admissions in the United States, patients who underwent HT had no in-hospital mortality, in contrast to the high in-hospital-mortality observed with surgical or transcatheter closure. Despite inherent selection biases, including survival to transplantation, HT was associated with favorable outcomes compared to surgical repair. While promising, these findings are preliminary due to the small sample size and selective nature of the patient cohort. Further studies are required before HT can be broadly recommended as a primary treatment option.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"9 ","pages":"Article 100278"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHLT Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950133425000734","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Ventricular septal rupture (VSR) is a devastating complication of myocardial infarction (MI), with high mortality, particularly in cardiogenic shock (CS). Heart transplantation (HT) has emerged as a potential alternative to surgery or transcatheter closure (TCC). This study evaluates contemporary trends and outcomes of HT in post-MI VSR using the National Inpatient Sample (NIS) database.

Objectives

To assess in-hospital mortality and resource utilization of HT compared to surgical repair or TCC for post-MI VSR with CS.

Methods

We analyzed NIS data (2016–2021) for MI-VSR hospitalizations with CS. Patients undergoing HT were compared to those receiving surgical repair or TCC. Primary and secondary endpoints included in-hospital mortality (IHM), total hospital charges (TOTCHG), and length of stay (LOS). Multivariable logistic regression adjusted for age, sex, race, comorbidities, and hospital characteristics, with surgical repair as the control.

Results

Of 2,514,025 acute MI hospitalizations, 4765 (0.20%) had VSR. IHM was 82% with CS vs. 60% without. Among VSR-CS patients, 30 (1.2%) underwent HT, 600 (24.1%) surgical repair, 225 (9.2%) TCC, and 1635 (65%) medical therapy. IHM was 0% for HT vs. 66% (surgery), 75% (TCC), and 97% (medical therapy). All HT patients received mechanical circulatory support [IABP (50%), Impella (27%), ECMO ± Impella (10%), ECMO (13%)].). Patients undergoing HT had an average LOS approximately 20 days longer than those treated surgically (p = 0.004; 95% CI: 13.78–47.29) and 15 days longer with TCC (p = 0.008; 95% CI: 19.32–54.23). Similarly, mean total hospital charges (TOTCHG) were higher for HT patients ($1,456,693) compared to surgical repair ($325,032; p = 0.001; 95% CI: $145,002–$634,293) and TCC ($210,032; p = 0.001; 95% CI: $119,230–$542,200).

Conclusions

From 2016 to 2021, among VSR-CS admissions in the United States, patients who underwent HT had no in-hospital mortality, in contrast to the high in-hospital-mortality observed with surgical or transcatheter closure. Despite inherent selection biases, including survival to transplantation, HT was associated with favorable outcomes compared to surgical repair. While promising, these findings are preliminary due to the small sample size and selective nature of the patient cohort. Further studies are required before HT can be broadly recommended as a primary treatment option.
梗死后室间隔破裂的心脏移植:来自2016-2021年国家住院患者数据库的当代结果
室间隔破裂(VSR)是心肌梗死(MI)的一种破坏性并发症,死亡率高,特别是心源性休克(CS)。心脏移植(HT)已成为手术或经导管闭合(TCC)的潜在替代方案。本研究利用国家住院患者样本(NIS)数据库评估了心肌梗死后VSR中HT的当代趋势和结果。目的评价与手术修复或TCC相比,HT治疗mi后VSR合并CS的住院死亡率和资源利用率。方法分析2016-2021年MI-VSR合并CS住院的NIS数据。将接受HT的患者与接受手术修复或TCC的患者进行比较。主要和次要终点包括住院死亡率(IHM)、总住院费用(TOTCHG)和住院时间(LOS)。多变量logistic回归校正了年龄、性别、种族、合并症和医院特征,以手术修复为对照。结果2,514,025例急性心肌梗死住院患者中,4765例(0.20%)发生VSR。有CS的IHM为82%,没有CS的IHM为60%。在VSR-CS患者中,30例(1.2%)接受了HT, 600例(24.1%)接受了手术修复,225例(9.2%)接受了TCC, 1635例(65%)接受了药物治疗。HT组IHM为0%,手术组为66%,TCC组为75%,药物治疗组为97%。所有HT患者均接受机械循环支持[IABP (50%), Impella (27%), ECMO±Impella (10%), ECMO(13%)]。接受HT治疗的患者的平均LOS比手术治疗的患者长约20天(p = 0.004;95% CI: 13.78-47.29), TCC患者时间延长15天(p = 0.008;95% ci: 19.32-54.23)。同样,HT患者的平均总住院费用(TOTCHG)(1,456,693美元)高于手术修复(325,032美元;P = 0.001;95% CI: 145,002 - 634,293美元)和TCC(210,032美元;P = 0.001;95% ci: 119,230 - 542,200美元)。从2016年到2021年,在美国接受VSR-CS治疗的患者中,接受HT治疗的患者没有院内死亡率,与手术或经导管关闭术观察到的高院内死亡率形成对比。尽管存在固有的选择偏差,包括存活到移植,但与手术修复相比,HT具有良好的预后。虽然有希望,但由于样本量小和患者队列的选择性,这些发现是初步的。在HT被广泛推荐为主要治疗选择之前,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信